Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Fate Therapeutics (FATE) Catches Eye: Stock Jumps 19.1%
Fate Therapeutics, Inc. (FATE - Free Report) was a big mover last session, as its shares rose over 19% on the day. The move came on the back of FDA’s Fast Track Designation for the company’s ProTmune. This also led to far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $1.52 to $1.86 in the past one-month time frame.
None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Fate Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%
FATE THERAPEUTC Price
FATE THERAPEUTC Price | FATE THERAPEUTC Quote
A better-ranked stock in the Biomedical space is Neogenomics Inc. (NEO - Free Report) which sports a Zacks Rank #1(Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>